Követés
György M. Keserű
György M. Keserű
E-mail megerősítve itt: ttk.mta.hu - Kezdőlap
Cím
Hivatkozott rá
Hivatkozott rá
Év
Encyclopedia of Pharmaceutical Technology: Volume 6
J Swarbrick
CRC press, 2013
17392013
The role of ligand efficiency metrics in drug discovery
AL Hopkins, GM Keserü, PD Leeson, DC Rees, CH Reynolds
Nature reviews Drug discovery 13 (2), 105-121, 2014
10992014
The influence of lead discovery strategies on the properties of drug candidates
GM Keserü, GM Makara
nature reviews Drug Discovery 8 (3), 203-212, 2009
7012009
Expanding the medicinal chemistry synthetic toolbox
J Boström, DG Brown, RJ Young, GM Keserü
Nature Reviews Drug Discovery 17 (10), 709-727, 2018
5492018
Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease
A Douangamath, D Fearon, P Gehrtz, T Krojer, P Lukacik, CD Owen, ...
Nature communications 11 (1), 5047, 2020
4522020
Finding the sweet spot: the role of nature and nurture in medicinal chemistry
MM Hann, GM Keserü
Nature reviews Drug discovery 11 (5), 355-365, 2012
4492012
Hit discovery and hit-to-lead approaches
GM Keserű, GM Makara
Drug discovery today 11 (15-16), 741-748, 2006
4072006
GPCRdb in 2021: integrating GPCR sequence, structure and function
AJ Kooistra, S Mordalski, G Pándy-Szekeres, M Esguerra, A Mamyrbekov, ...
Nucleic Acids Research 49 (D1), D335-D343, 2021
3232021
Design principles for fragment libraries: maximizing the value of learnings from pharma fragment-based drug discovery (FBDD) programs for use in academia
GM Keserű, DA Erlanson, GG Ferenczy, MM Hann, CW Murray, ...
Journal of medicinal chemistry 59 (18), 8189-8206, 2016
2322016
Impact of lipophilic efficiency on compound quality
A Tarcsay, K Nyíri, GM Keserű
Journal of medicinal chemistry 55 (3), 1252-1260, 2012
1862012
Optimization of virtual screening protocols: FlexX based virtual screening for COX-2 inhibitors reveals the importance of tailoring screen parameters
A Bauer, Z Kovári, GM Keserű
Journal of Molecular Structure: THEOCHEM 676 (1-3), 1-5, 2004
1822004
Thermodynamics guided lead discovery and optimization
GG Ferenczy, GM Keserű
Drug discovery today 15 (21-22), 919-932, 2010
1522010
Pharmacologic inhibition of STAT5 in acute myeloid leukemia
B Wingelhofer, B Maurer, EC Heyes, AA Cumaraswamy, A Berger-Becvar, ...
Leukemia 32 (5), 1135-1146, 2018
1452018
A high throughput luminescent assay for glycogen synthase kinase-3 β inhibitors
A Baki, A Bielik, L Molnár, G Szendrei, GM Keserü
Assay and drug development technologies 5 (1), 75-84, 2007
1452007
Contributions of molecular properties to drug promiscuity: miniperspective
Á Tarcsay, GM Keserű
Journal of medicinal chemistry 56 (5), 1789-1795, 2013
1422013
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods
GM Keserü
Bioorganic & medicinal chemistry letters 13 (16), 2773-2775, 2003
1412003
Recent advances in the prediction of blood–brain partitioning from molecular structure
M Lobell, L Molnár, GM Keserü
Journal of pharmaceutical sciences 92 (2), 360-370, 2003
1392003
Validity of ligand efficiency metrics
CW Murray, DA Erlanson, AL Hopkins, GM Keserü, PD Leeson, ...
ACS medicinal chemistry letters 5 (6), 616-618, 2014
1342014
Comparative evaluation of covalent docking tools
A Scarpino, GG Ferenczy, GM Keserű
Journal of Chemical Information and Modeling 58 (7), 1441-1458, 2018
1312018
Virtual fragment docking by Glide: a validation study on 190 protein− fragment complexes
M Sandor, R Kiss, GM Keserű
Journal of Chemical Information and Modeling 50 (6), 1165-1172, 2010
1242010
A rendszer jelenleg nem tudja elvégezni a műveletet. Próbálkozzon újra később.
Cikkek 1–20